Recombinant human neuregulin-1 beta

Drug Profile

Recombinant human neuregulin-1 beta

Alternative Names: Neucardin; rhNRG-1 - Zensun

Latest Information Update: 19 Oct 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Zensun
  • Developer Zensun (Shanghai) Sci & Tech
  • Class Anti-ischaemics; Glycoproteins; Heart failure therapies; Neuregulins; Peptide fragments
  • Mechanism of Action Neuregulin-1 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Chronic heart failure

Most Recent Events

  • 26 Jun 2015 Recombinant human neuregulin-1 beta is still in phase-II development for Chronic heart failure in USA (SC)
  • 14 May 2013 Safety and efficacy data from phase II trials in Chronic heart failure released by Zensun
  • 31 Dec 2012 Preregistration for Chronic heart failure in China (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top